Postmarketing experience with topiramate and cognition

Epilepsia

Volumn 42, Issue 9, 2001, Pages 1134-1140

  Tatum IV, W O ^a,h   French, J A ^b   Faught, E ^c   Morris III, G L ^d   Liporace, J ^e   Kanner, A ^f   Goff, S L ^g   Winters, L ^b   Fix, A ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c The University of Alabama at Birmingham   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF SOUTH FLORIDA   (United States)

^h University of Pennsylvania ^*  (United States)

Author keywords

Antiepileptic drugs; Cognitive dysfunction; Epilepsy; Psychomotor slowing; Seizures; Topiramate

Indexed keywords

TOPIRAMATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPILEPSY; FEMALE; FOCAL EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MULTICENTER STUDY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOSIS; SIDE EFFECT; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; COGNITION; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; FRUCTOSE; HUMANS; INFANT; MALE; MIDDLE AGED; MULTICENTER STUDIES; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; PSYCHOMOTOR DISORDERS; RISK FACTORS;

EID: 0034790271     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2001.41700.x     Document Type: Article

References (35)

1. Cognitive effects of epilepsy and of antiepileptic medications
2. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs
3. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, 600-mg dosages
4. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, 1000-mg dosages
5. Double-blind placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures
6. Double-blind placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy
7. Double-blind placebo-controlled study of topiramate in patients with refractory seizures
8. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome
9. Long-term experience with topiramate in Lennox-Gastaut syndrome
10. A study of topiramate in primary generalized tonic-clonic seizures
11. Topiramate: A review of preclinical, pharmacokinetic, and clinical data
12. Long-term efficacy and safety of topiramate
13. Long-term follow-up of patients treated with topiramate for partial seizures
14. Evaluation of case reports of aplastic anemia among patients treated with felbamate
15. Ventricular asystole during vagus nerve stimulation for epilepsy in humans
16. Psychiatric adverse events caused by topiramate and lamotrigine: A postmarketing prevalence and risk factor study
17. Cognitive adverse effects of antiepileptic drugs
18. Post-marketing surveillance for adverse events after vaccination: The national Vaccine Adverse Event Reporting System (VAERS)
19. Cognitive effects of topiramate, gabapentin, andlamotrigine in healthy young adults
20. Long term treatment with topiramate in refractory partial epilepsy: A two year follow-up study
21. Long-term efficacy in anopen-label trial of topiramate
22. Topiramate: A new antiepileptic drug for refractory epilepsy
23. Topiramate monotherapy for partial onset seizures
24. Safety of topiramate: Adverse events and relationship to dosing
25. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy duringmonotherapy and concomitant therapy
26. Comparative cognitive effects of phenobarbital, phenytoin, and valproate in healthy subjects
27. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalizedtonic-clonic seizures
28. Long-term cognitive effects of topiramate
29. Effects of topiramate on attention over time
30. The new antiepileptic drugs: A systemic review of their efficacy and tolerability
31. The beneficial effect of slowing the initial titration rate of topiramate
32. Assessing cognitive effects of a new AED without the bias of practice effects
33. A multicenter randomized clinical study to evaluate the effect of cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial onset seizures
34. Topiramate in clinical practice: First year's licensing experience in a specialist epilepsy clinic